CA3237156A1 - Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions - Google Patents

Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions Download PDF

Info

Publication number
CA3237156A1
CA3237156A1 CA3237156A CA3237156A CA3237156A1 CA 3237156 A1 CA3237156 A1 CA 3237156A1 CA 3237156 A CA3237156 A CA 3237156A CA 3237156 A CA3237156 A CA 3237156A CA 3237156 A1 CA3237156 A1 CA 3237156A1
Authority
CA
Canada
Prior art keywords
compound
imidazo
pyrazol
methoxy
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237156A
Other languages
English (en)
French (fr)
Inventor
Benoit Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3237156A1 publication Critical patent/CA3237156A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3237156A 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions Pending CA3237156A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207942.0 2021-11-12
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
PCT/US2022/049695 WO2023086564A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (1)

Publication Number Publication Date
CA3237156A1 true CA3237156A1 (en) 2023-05-19

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237156A Pending CA3237156A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Country Status (10)

Country Link
US (3) US11814383B2 (https=)
EP (2) EP4180428A1 (https=)
JP (1) JP2024543413A (https=)
CN (1) CN118843624A (https=)
AU (1) AU2022387516A1 (https=)
CA (1) CA3237156A1 (https=)
IL (1) IL312625A (https=)
MX (1) MX2024005766A (https=)
TW (1) TW202334143A (https=)
WO (1) WO2023086564A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) * 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CN121464134A (zh) * 2023-05-17 2026-02-03 中枢疗法公司 咪唑并[4,5-b]吡啶化合物的颗粒、药物组合物及其在治疗医学病症中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
JP7472103B2 (ja) * 2018-08-22 2024-04-22 クルゲン（シャンハイ），インク． トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Also Published As

Publication number Publication date
TW202334143A (zh) 2023-09-01
JP2024543413A (ja) 2024-11-21
US20250250274A1 (en) 2025-08-07
IL312625A (en) 2024-07-01
WO2023086564A1 (en) 2023-05-19
CN118843624A (zh) 2024-10-25
US11814383B2 (en) 2023-11-14
EP4180428A1 (en) 2023-05-17
AU2022387516A1 (en) 2024-05-23
US12291528B2 (en) 2025-05-06
EP4430043A1 (en) 2024-09-18
EP4430043A4 (en) 2025-11-05
MX2024005766A (es) 2024-07-29
US20230151008A1 (en) 2023-05-18
US20240150352A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
US11802122B2 (en) 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
US12516046B2 (en) 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
US12291528B2 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
JP7827911B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP7198820B2 (ja) 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
TW202019900A (zh) Ptpn11抑制劑
JP7787811B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP2024509998A (ja) 抗菌化合物
JP2018076365A (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
CA2769149A1 (en) Compositions and methods for treating parkinson's disease
KR100882925B1 (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO2009050554A2 (en) Treatment of central nervous system disorders
CN100491378C (zh) 新的取代四环咪唑衍生物,其制备方法,包含它们的药物组合物及它们作为药物的用途
EP2514753B1 (en) 6,7-Dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation
WO2026059838A1 (en) Indazole derivatives useful as hcn1/hcn 2 modulators
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
HK40087766A (zh) 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241101

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241101

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241101

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107